The role of C4d and donor specific antibodies in face and hand transplantation—a systematic review
Huelsboemer L, Moscarelli J, Dony A, Boroumand S, Kochen A, Knoedler L, Yu C, Hauc S, Stögner V, Formica R, Lian C, Murphy G, Pomahac B, Kauke-Navarro M. The role of C4d and donor specific antibodies in face and hand transplantation—a systematic review. Frontiers In Transplantation 2024, 3: 1442006. PMID: 39291278, PMCID: PMC11405992, DOI: 10.3389/frtra.2024.1442006.Peer-Reviewed Original ResearchDonor-specific antibodiesSerum donor-specific antibodiesAntibody-mediated rejectionHigher rejection gradesVascularized composite allotransplantationC4d depositionRejection gradeCellular rejectionRejection episodesSpecific antibodiesDonor-specific antibody statusManagement of antibody-mediated rejectionFace transplantationAcute cellular rejectionAcute rejection episodesAssociated with high gradeTime of biopsyAntibody mediated rejectionFisher's exact testMann-Whitney U testSystematic review of electronic databasesMechanisms of rejectionSystematic reviewReview of electronic databasesC4d stainingEvolution of Vascularized Composite Allotransplantation
Huelsboemer L, Pomahac B. Evolution of Vascularized Composite Allotransplantation. 2024, 15-27. DOI: 10.1007/978-3-031-57132-9_3.Peer-Reviewed Original ResearchVascularized composite allotransplantationSolid organ transplantationProlongation of ischemia timeReconstruction of complex tissue defectsContext of vascularized composite allotransplantationDevelopment of non-toxicTolerogenic strategiesChronic rejectionImmunosuppressive medicationsTolerance inductionComplex tissue defectsPatient selectionIschemia timeC-reactive protein orchestrates acute allograft rejection in vascularized composite allotransplantation via subset-selective monocyte activation
Kiefer J, Zeller J, Schneider L, Thomé J, McFadyen J, Hoerbrand I, Lang F, Deiss E, Bogner B, Schaefer A, Chevalier N, Horner V, Kreuzaler S, Kneser U, Kauke-Navarro M, Braig D, Woollard K, Pomahac B, Peter K, Eisenhardt S. C-reactive protein orchestrates acute allograft rejection in vascularized composite allotransplantation via subset-selective monocyte activation. Journal Of Advanced Research 2024 PMID: 38992424, DOI: 10.1016/j.jare.2024.07.007.Peer-Reviewed Original ResearchAcute allograft rejectionC-reactive proteinVascularized composite allotransplantationAllograft rejectionAcute rejectionAllograft survivalGraft rejectionAttenuate acute allograft rejectionPreventing acute allograft rejectionImmune responseLong-term allograft survivalFacial vascularized composite allotransplantationClinical allograft rejectionReduced allograft survivalChronic allograft rejectionIntravital imagingNon-classical monocytesMarkers of inflammationAcute-phase reactantsImmune-inflammatory reactionPro-inflammatory propertiesMononuclear phagocyte systemAcute-phase responseGraft infiltrationInnate immune responseImmune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions
Knoedler L, Dean J, Diatta F, Thompson N, Knoedler S, Rhys R, Sherwani K, Ettl T, Mayer S, Falkner F, Kilian K, Panayi A, Iske J, Safi A, Tullius S, Haykal S, Pomahac B, Kauke-Navarro M. Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions. Frontiers In Immunology 2024, 15: 1372862. PMID: 38650942, PMCID: PMC11033354, DOI: 10.3389/fimmu.2024.1372862.Peer-Reviewed Original ResearchConceptsRegulatory myeloid cellsSolid organ transplantationVascularized composite allotransplantationMesenchymal stromal cellsT cellsTransplant patientsCellular therapyChimeric antigen receptor T cellsTransplant surgerySide effectsIncreased risk of malignancyProgression to chronic rejectionAcute rejection ratesPerioperative treatment strategiesRegulatory T cellsPromote immune toleranceRisk of malignancySystemic side effectsRelated side effectsCell typesImprove transplant survivalCAR-TCell therapy applicationsImmunosuppressive regimensChronic rejectionLymphadenopathy and lymph node rejection following facial vascularized composite allotransplantation
Kauke-Navarro M, Sadigh S, Lee C, Panayi A, Knoedler L, Knoedler S, Stoegner V, Huelsboemer L, Jamil A, Ko C, Lian C, Murphy G, Pomahac B. Lymphadenopathy and lymph node rejection following facial vascularized composite allotransplantation. Journal Of Plastic Reconstructive & Aesthetic Surgery 2024, 91: 268-275. PMID: 38430863, DOI: 10.1016/j.bjps.2024.02.024.Peer-Reviewed Original ResearchLymph nodesVascularized composite allograftsGranzyme BDonor-derived immune cellsFacial vascularized composite allograftMedian time of presentationFacial vascularized composite allotransplantationImmunological processesGranzyme B expressionCytotoxic T cellsNecrotizing histiocytic lymphadenitisHead and neckRetrospective cohort studyTime of presentationStages of follow-upCoexistence of donorFace transplant patientsBilateral adenopathyIncreased histiocytesSuperficial lymph nodesVascularized composite allotransplantationBilateral lymphadenopathyAllograft rejectionTransplant patientsDendritic cells